share_log

Cardio Diagnostics | 8-K: Current report

Cardio Diagnostics | 8-K: Current report

Cardio Diagnostics | 8-K:重大事件
SEC announcement ·  04/02 16:37
Moomoo AI 已提取核心信息
Cardio Diagnostics Holdings Inc. has announced that starting from April 3, 2024, its senior management will use a new set of materials for presentations to current and potential investors. These materials are part of the March 2024 Investor Presentation, which is now incorporated into the company's Form 8-K filing with the SEC and will also be available on Cardio Diagnostics' website. The company, listed on The Nasdaq Stock Market LLC under the symbol CDIO for its common stock and CDIOW for its redeemable warrants, is classified as an emerging growth company. The information provided in the Investor Presentation is not considered filed for SEC purposes and is not incorporated by reference into any registration statement as per the Securities Exchange Act of 1934, except as explicitly stated in such filings.
Cardio Diagnostics Holdings Inc. has announced that starting from April 3, 2024, its senior management will use a new set of materials for presentations to current and potential investors. These materials are part of the March 2024 Investor Presentation, which is now incorporated into the company's Form 8-K filing with the SEC and will also be available on Cardio Diagnostics' website. The company, listed on The Nasdaq Stock Market LLC under the symbol CDIO for its common stock and CDIOW for its redeemable warrants, is classified as an emerging growth company. The information provided in the Investor Presentation is not considered filed for SEC purposes and is not incorporated by reference into any registration statement as per the Securities Exchange Act of 1934, except as explicitly stated in such filings.
Cardio Diagnostics Holdings Inc.宣布,从2024年4月3日起,其高级管理层将使用一套新的材料向现有和潜在投资者进行演讲。这些材料是2024年3月投资者演示文稿的一部分,该报告现已纳入该公司向美国证券交易委员会提交的8-K表格,也将在Cardio Diagnostics的网站上公布。该公司在纳斯达克股票市场有限责任公司上市,普通股的股票代码为CDIO,可赎回认股权证的代码为CDIOW,被列为新兴成长型公司。根据1934年《证券交易法》,除非此类文件中明确规定,否则投资者简报中提供的信息不被视为出于美国证券交易委员会的目的提交,也未以引用方式纳入任何注册声明中。
Cardio Diagnostics Holdings Inc.宣布,从2024年4月3日起,其高级管理层将使用一套新的材料向现有和潜在投资者进行演讲。这些材料是2024年3月投资者演示文稿的一部分,该报告现已纳入该公司向美国证券交易委员会提交的8-K表格,也将在Cardio Diagnostics的网站上公布。该公司在纳斯达克股票市场有限责任公司上市,普通股的股票代码为CDIO,可赎回认股权证的代码为CDIOW,被列为新兴成长型公司。根据1934年《证券交易法》,除非此类文件中明确规定,否则投资者简报中提供的信息不被视为出于美国证券交易委员会的目的提交,也未以引用方式纳入任何注册声明中。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息